...
首页> 外文期刊>Chronic respiratory disease. >Presentation, management and mortality after a first MI in people with and without asthma: A study using UK MINAP data
【24h】

Presentation, management and mortality after a first MI in people with and without asthma: A study using UK MINAP data

机译:患有和不患有哮喘的人首次MI后的表现,治疗和死亡率:一项使用UK MINAP数据的研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Asthma has been associated with a higher incidence of myocardial infarction (MI), higher prevalence of MI risk factors and higher burden of cardiovascular diseases. However, detailed associations between the presentation and initial management at the time of MI and post-MI outcomes in people with asthma compared to the general population have not been studied. A total of 300,161 people were identified with a first MI over the period 2003–2013 in the Myocardial Ischaemia National Audit Project database, of whom 8922 (3%) had asthma. Logistic regression was used to compare presentation, in-hospital care, in-hospital and 180-day post-discharge all-cause mortality in people with and without asthma adjusting for demographics and comorbidities, diagnosis on arrival and secondary prevention. People with asthma were more likely to have a delay in their MI diagnosis following an STEMI (ST-elevation myocardial infarction; odds ratio (OR) 1.38, confidence interval CI 1.06–1.79) but not an nSTEMI (non-ST-elevation myocardial infarction; OR 1.04, CI 0.92–1.17) compared to people without asthma and a delay in reperfusion (OR 1.19, CI 1.09–1.30) following an STEMI. They were much less likely to be discharged on a beta blocker following an STEMI or nSTEMI (OR 0.24, CI 0.21–0.28 and OR 0.27, CI 0.24–0.30, respectively). There was no difference in in-hospital or 180-day mortality (OR 0.98, CI 0.59–1.62 and OR 0.99, CI 0.72–1.36) following an STEMI or nSTEMI (OR 0.89, CI 0.47–1.68 and OR 1.05, CI 0.85–1.28). Although people with asthma were more likely to have a delay in diagnosis following an STEMI but not an nSTEMI compared to the general population, were more likely to have a delay in reperfusion therapy and were much less likely to receive beta blockers following an STEMI or nSTEMI, there was no difference in the prescriptions of other secondary prevention medications. None of the differences in presentation or management were associated with an increase in all-cause in-hospital or 180-day mortality in people with asthma compared to the general population.
机译:哮喘与心肌梗死(MI)的发生率更高,MI危险因素的患病率更高以及心血管疾病的负担更高有关。然而,与普通人群相比,哮喘患者的表现和MI时的初始管理与MI后结果之间的详细关联尚未得到研究。在“心肌缺血国家审计项目”数据库中,2003年至2013年期间共鉴定出300161人患有首例心梗,其中8922人(占3%)患有哮喘。使用Logistic回归分析比较有无哮喘患者的就诊,住院治疗,院内和出院后180天全因死亡率,并根据人口统计学和合并症进行调整,到达诊断和二级预防。患有哮喘的人更有可能在STEMI(ST抬高型心肌梗塞;比值比(OR)1.38,置信区间CI 1.06-1.79)后延迟MI诊断,而没有nSTEMI(非ST抬高型心肌梗塞)。 ;相比于没有哮喘和STEMI后再灌注延迟的人(OR 1.19,CI 1.09-1.30),OR为1.04,CI为0.92-1.17)。在发生STEMI或nSTEMI后,它们在β受体阻滞剂上放电的可能性要小得多(分别为OR 0.24,CI 0.21-0.28和OR 0.27,CI 0.24-0.30)。 STEMI或nSTEMI后院内或180天死亡率无差异(OR 0.98,CI 0.59–1.62和OR 0.99,CI 0.72-1.36)(OR 0.89,CI 0.47–1.68和OR 1.05,CI 0.85–1) 1.28)。尽管与普通人群相比,哮喘患者在STEMI术后更容易延迟诊断,而在nSTEMI方面没有延迟,但在再灌注治疗中延迟的可能性更大,而在STEMI或nSTEMI之后接受β受体阻滞剂的可能性要小得多。 ,其他二级预防药物的处方没有差异。与普通人群相比,哮喘患者的表现或管理差异均与全因住院或180天死亡率的增加无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号